您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2016, Vol. 54 ›› Issue (6): 82-86.doi: 10.6040/j.issn.1671-7554.0.2015.713

• • 上一篇    下一篇

免疫性疾病患者T-SPOT.TB筛查结果及影响因素

盖林林1*,管立学2*,李海波2,褚锦锦2,朱芸3,李明3   

  1. 1.潍坊医学院临床检验诊断学教研室, 山东 潍坊 261053;2.潍坊市人民医院中心实验室, 山东 潍坊 261041;3.潍坊市人民医院风湿免疫科, 山东 潍坊 261041
  • 收稿日期:2015-07-29 出版日期:2016-06-20 发布日期:2016-06-20
  • 通讯作者: 管立学. E-mail:1832996383@qq.com*并列第一作者 E-mail:1832996383@qq.com
  • 基金资助:
    潍坊市科技发展计划(卫生部分)(2015WS005)

Screening results and influencing factors of T-SPOT.TB assay in patients with autoimmune rheumatic diseases

GAI Linlin1*, GUAN Lixue2*, LI Haibo2, CHU Jinjin2, ZHU Yun3, LI Ming3   

  1. 1. Department of Clinical Laboratory Diagnostics, Weifang Medical University, Weifang 261053, Shandong, China;
    2. Central Laboratory, Weifang Peoples Hospital, Weifang 261041, Shandong, China;
    3. Department of Rheumatology, Weifang Peoples Hospital, Weifang 261041, Shandong, China
  • Received:2015-07-29 Online:2016-06-20 Published:2016-06-20

PDF (PC)

3745

摘要： 目的 探讨风湿免疫性疾病患者潜伏结核感染(LTBI)状况及影响结核感染T细胞斑点试验(T-SPOT.TB)结果的相关因素。方法 选取2013年6月至2014年6月风湿免疫性疾病患者223例(病例组)和健康人群53例(健康对照组),抽取外周血,应用结核分枝杆菌特异性抗原ESAT-6和CFP-10刺激,对致敏T细胞应答反应进行检测,并记录糖皮质激素和改善病情的抗风湿药物(DMARDs)应用情况及LTBI高危因素。 结果 病例组T-SPOT.TB阳性检出率20.18%,显著高于健康对照组5.66%;病例组发生结核菌感染的相对风险(OR)是健康对照组的4.21倍(95%CI:1.21~14.70, P<0.05)。病例组T-SPOT.TB阳性检出率和发生LTBI的风险存在明显差异(P<0.01),结节性红斑患者T-SPOT.TB阳性检出率高达44%,发生结核菌感染的风险是健康对照组的13.11倍(95%CI:3.44~49.98, P<0.01);类风湿关节炎患者阳性率21.16%(OR=4.47,95%CI: 1.06~18.82, P<0.05);其他风湿免疫性疾病T-SPOT.TB阳性检出率10.0%~33.34%(OR=1.85~8.33, P>0.05)。T-SPOT.TB阳性和阴性应用糖皮质激素和DMARDs 治疗患者所占比例差异均无统计学意义(P>0.05);既往TB感染史和CT检查结果异常与T-SPOT.TB阳性结果呈显著相关性(P<0.01)。 结论 风湿免疫性疾病患者发生LTBI风险是健康对照组的4.21倍,T-SPOT.TB试验受激素及DMARDs药物影响较小,是LTBI筛查的有效方法。

关键词: 风湿免疫性疾病, 结核感染相对风险度, 筛查, 潜伏结核感染, 影响因素

Abstract: Objective To investigate the status of latent tuberculosis infection(LTBI)in patients with autoimmune rheumatic diseases and the factors associated with a T-cell enzyme-linked immunospot assay(T-SPOT.TB). Methods During June 2013 and June 2014, a total of 223 patients with various autoimmune rheumatic diseases(patient group)and 53 healthy subjects(control group)were enrolled and screened for LTBI by T-SPOT.TB tests. Data on tuberculosis exposure, use of glucosteroid and disease-modifying anti-rheumatic drugs(DMARDs), BCG vaccination history and abnormal CT scans were collected. Miettinen test was used to estimate odds ratios(OR)and 95% confidence intervals(CI). Results T-SPOT.TB-positive rate was 20.18% in the patient group and 5.66% in the control group, and the patient group had higher risk of LTBI(OR=4.21, 95%CI: 1.21-14.70, P<0.05). There were significant 山 东 大 学 学 报 (医 学 版)54卷6期 -盖林林,等.免疫性疾病患者T-SPOT.TB筛查结果及影响因素 \=-differences in T-SPOT.TB-positive rate and OR among various autoimmune rheumatic diseases. The T-SPOT.TB positive rate was 44.0% in patients with erythema nodosumts(OR=13.11, 95%CI: 3.44-49.98, P<0.01), and 21.16% in patients with rheumatoid arthritis(RA)(OR=4.47, 95%CI: 1.06-18.82, P<0.05), obviously higher than that of controls. The T-SPOT.TB positive rate in patients with other rheumatic autoimmune diseases was 10.0%-33.34%(OR=1.85-8.3, P>0.05). There were no significant differences between the proportions of patients treated with glucocorticoid and DMARDs in T-SPOT.TB-positive and T-SPOT.TB-negative groups(P>0.05). Previous active TB and an abnormal CT examination were significantly associated with T-SPOT.TB-positive rate(P<0.01). Conclusion Patients with autoimmune rheumatic diseases are at increased risk of LTBI(OR=4.21). The glucocorticoid and DMARDs treatment have little effect on T-SPOT.TB results. It is an effective method to screen LTBI with T-SPOT.TB in patients with autoimmune rheumatic diseases.

Key words: Influencing factors, Relative risk of tuberculosis infection, Latent tuberculosis infection, Screening, Autoimmune rheumatic diseases

中图分类号: 

  • R735.2
[1] Vadillo Font C, Hernández-García C, Pato E, et al. Incidence and characteristics of tuberculosis in patients with autoimmune rheumatic diseases[J]. Rev Clin Esp, 2003, 203(4): 178-182.
[2] Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden[J]. Arthritis Rheum, 2005, 52(7): 1986-1992.
[3] He D, Bai F, Zhang S, et al. High incidence of tuberculosis infection in rheumatic diseases and impact for chemoprophylactic prevention of tuberculosis activation during biologics therapy[J]. Clin Vaccine Immunol, 2013, 20(6): 842-847.
[4] Beglinger C, Dudler J, Mottet C, et al. Screening for tuberculosis infection before the initiation of anti-TNF-alpha therapy[J]. Swiss Med Wkly, 2007, 137(43-44): 620-622.
[5] Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy[J]. Arthritis Rheum, 2004, 50(2): 372-379.
[6] 梁旗, 李鸿斌, 赵静. 酶联免疫斑点技术在风湿病患者结核诊断中的应用[J]. 中华风湿病杂志, 2009, 13(8): 578-580.
[7] Person AK, Pettit AC, Sterling TR. Diagnosis and treatment of latent tuberculosis infection: an update[J]. Curr Respir Care Rep, 2013, 2(4): 199-207.
[8] 吴妹英, 王霞芳, 肖玉梅, 等. 酶联免疫斑点法在快速诊断活动性肺结核中的应用[J]. 中华实验和临床感染病杂志(电子版), 2009, 3(2): 1-4.
[9] Murakami S, Takeno M, Kirino Y, et al. Screening of tuberculosis by interferon-gamma assay before biologic therapy for rheumatoid arthritis[J]. Tuberculosis(Edinb), 2009, 89(2): 136-141.
[10] QIU Haomin, ZHANG Shu, XUE Yu, et al. Use of an enzyme-linked immunospot assay for diagnosing latent tuberculosis infection in rheumatic diseases[J]. Chin J Rheumatol, 2010, 14(5): 301-304.
[11] Xie X, Chen JW, Li F, et al. A T-cell-based enzyme-linked immunospot assay for tuberculosis screening in Chinese patients with rheumatic diseases receiving infliximab therapy[J]. Clin Exp Med, 2011, 11(3): 155-161.
[1] 孙佳丽,王亮,王长凤,张杰,郭磊. Klippel-Trenaunay综合征儿童情绪与行为特征及其影响因素[J]. 山东大学学报 (医学版), 2026, 64(3): 78-82.
[2] 宋一鸣,王佳丰,韩晓娟,杜怡峰. 脑维持与认知功能:测量、影响因素和机制[J]. 山东大学学报 (医学版), 2026, 64(1): 1-7.
[3] 徐欣颖,颜伟,石兴龙,岳芳,吕婧,乔颖异,张宇琦,程传龙,左慧,李秀君. 山东省滨州市手足口病的流行特征及影响因素[J]. 山东大学学报 (医学版), 2026, 64(1): 118-125.
[4] 孙爽爽,仉率杰,张伯韬,袁莹,于媛媛,薛付忠. 基于真实世界研究的18~50岁人群急性缺血性卒中影响因素[J]. 山东大学学报 (医学版), 2025, 63(9): 40-46.
[5] 王宁,郝秀梅,牛翔,黄金明,徐静雅. 中国中老年高血糖、血脂异常、高血压人群健康体检服务利用现状及影响因素[J]. 山东大学学报 (医学版), 2025, 63(7): 82-91.
[6] 张永媛,王清亮,连雪洪. 山东省某三级综合医院罕见病患者住院费用结构变动情况及影响因素[J]. 山东大学学报 (医学版), 2025, 63(5): 111-119.
[7] 陈瑛翼,游倩,王意,张帆,李凤,季舒铭,徐浩源,饶志勇. 办公室职员肌肉质量减少预测模型的开发与验证[J]. 山东大学学报 (医学版), 2025, 63(4): 26-35.
[8] 刘国伟,翟艳,王薇,吕军城. 潍坊市某城区65岁及以上老年人社会适应能力现状及其影响因素[J]. 山东大学学报 (医学版), 2025, 63(2): 104-110.
[9] 穆弘杰,卢伟,吕军城. 居民抑郁、焦虑症状和心理健康素养现况及影响因素分析[J]. 山东大学学报 (医学版), 2025, 63(12): 105-111.
[10] 刘峰,马彩霞,李春燕,程海英,靳乐雨,刘仲,李学文. 2023年11月流感高峰期济南市大学生流感样病例发生情况及影响因素[J]. 山东大学学报 (医学版), 2024, 62(7): 91-97.
[11] 景睿,张文茜,董卉,董怡然,于胜男,段勇,闫芹,赵传禄,李秀君,汪卫兵. 济南市大一新生结核病防治知信行现状及行为影响因素[J]. 山东大学学报 (医学版), 2024, 62(2): 101-107.
[12] 冯绪强,高萍,孙超,陶琳,闫根全,冷冰. 替加环素治疗感染性疾病临床疗效及影响因素[J]. 山东大学学报 (医学版), 2024, 62(12): 11-20.
[13] 张伯韬,仉率杰,孙爽爽,袁莹,胡锡峰,贾晓峰,于媛媛,薛付忠. 基于贝叶斯网络的缺血性脑卒中筛查模型构建[J]. 山东大学学报 (医学版), 2024, 62(11): 73-84.
[14] 于菲萍,李鑫,司明舒,张丹,苏永刚. 医学生医养结合认知程度与养老就业意愿[J]. 山东大学学报 (医学版), 2024, 62(11): 105-114.
[15] 刘凤祺,高峰,薛彩彩,乔秀梅,王金红. 高糖诱导PC12细胞损伤的影响因素及梓醇的保护作用[J]. 山东大学学报 (医学版), 2023, 61(7): 34-39.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发